Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design
European Eating Disorders Review · 2026
DOI: 10.1002/erv.70135 ↗At a glance
Fallbericht in European Eating Disorders Review, 2026. Written by Ashley Dunford and 4 co-authors. Institution: Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA. Major MEDLINE topics: Binge-Eating Disorder, Cognitive Behavioral Therapy, Gastric Inhibitory Polypeptide. 14 references. The full text is freely available in PubMed Central. Funded by: NIMH NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Objective
Many patients with larger bodies present to eating disorder (ED) treatment seeking weight loss. Whether glucose‐dependent insulinotropic polypeptide/glucagon‐like‐peptide receptor agonists (GIP/GLP‐1s) are helpful or harmful for such patients remains unknown. This single case experimental design study examined the effects of Tirzepatide (7.5 mg/0.05 mL), a GIP/GLP‐1 following 10‐session cognitive‐behavioural therapy (CBT‐T) in a patient with binge‐eating disorder (BED) and obesity.
Method
A 37‐year‐old female presented to an outpatient ED clinic with BED and a body mass index of 68.9 kg/m 2 . We assessed weekly and then monthly ED behaviours and cognitions using the Eating Disorder 15 (ED‐15) across two treatment phases: CBT‐T (3 months) and GIP/GLP‐1 administration (9 months).
Results
As hypothesised, ED cognitions and binge frequency decreased during CBT‐T. Also as hypothesised, during GIP/GLP‐1 phase, binge frequency remained low and dietary restraint absent. We observed continued reductions in ED cognitions and 39‐pound weight loss.
Discussion
GIP/GLP‐1 treatment after CBT‐T was followed by ED remission and weight loss without serious adverse events. CBT‐T skills may mitigate risk of disordered eating during GIP/GLP‐1 use. The combination of psychotherapy and GIP/GLP‐1s may further reduce binge‐eating and lead to weight loss. Research is needed to explore risks and benefits of GIP/GLP‐1s for patients with EDs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Mass General Brigham Multidisciplinary Eating Disorders Research Collaborative, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
ORCID profiles: Ashley Dunford, Stefania Yee, Jennifer J Thomas, Kamryn T Eddy, Esther Dechant
Funding
- NIMH NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Dunford, A., Yee, S., Thomas, J. J., Eddy, K. T., & Dechant, E. (2026). Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design. European Eating Disorders Review. https://doi.org/10.1002/erv.70135
Vancouver
Dunford A, Yee S, Thomas JJ, Eddy KT, Dechant E. Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design. European Eating Disorders Review. 2026. doi:10.1002/erv.70135
BibTeX
@article{Dunford2026,
author = {Dunford, Ashley and Yee, Stefania and Thomas, Jennifer J and Eddy, Kamryn T and Dechant, Esther},
title = {Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design},
journal = {European Eating Disorders Review},
year = {2026},
doi = {10.1002/erv.70135}
}
EUVIMED